← 18 Aug 2026 · All rebalances · 1 Oct 2026 →
Top 10 — Health Care — 1 Sep 2026
The ten as they stood on 1 Sep 2026. Scores, pillars and reasons are the ones recorded that day; nothing here is recomputed. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100.
The Top 10 score is a published weighted sum of percentile ranks, rebalanced on the first trading day of each month. A list is a published formula and its output, not a recommendation. Method version 3.
Get this list's changes every morning
One short email a day: who entered, who left, and the reason — with the score moves behind it.
Informational only — not financial advice. One email a day, unsubscribe in one click.
The ten
| # | Company | Why it was here | Sector | Score |
|---|---|---|---|---|
| 1 | AURINIA PHARMACEUTICALS INC (AUPH) | Profitability 95th (operating margin 48.4%, return on equity 59%).Profitability 95th (operating margin 48.4%, return on equity 59%) and financial health 90th (free cash flow margin 56.2%, debt to equity 0.1); weakest is capital return (54th, consecutive years of dividend increases 0 years, net share count bought back over the year 5.1). |
Health Care | 79.4 |
| 2 | Incyte (INCY) | Financial health 89th (free cash flow margin 33%, debt to equity 0).Financial health 89th (free cash flow margin 33%, debt to equity 0) and profitability 83rd (operating margin 30.6%, return on equity 29.6%); weakest is capital return (18th, consecutive years of dividend increases 0 years). |
Health Care | 73.6 |
| 3 | HARMONY BIOSCIENCES HLDG INC (HRMY) | Financial health 85th (free cash flow margin 35%, debt to equity 0.2).Financial health 85th (free cash flow margin 35%, debt to equity 0.2) and growth 84th (3-year revenue CAGR 25.6%, revenue growth year over year 24.3%); weakest is capital return (18th, consecutive years of dividend increases 0 years). |
Health Care | 72.4 |
| 4 | CAREDX INC (CDNA) | Trend 89th (trading above its 200-day average).Trend 89th (trading above its 200-day average) and financial health 81st (debt to equity 0, free cash flow margin 18.3%); weakest is valuation (50th, price to book 6, price to earnings 23.6). |
Health Care | 72.3 |
| 5 | KRYSTAL BIOTECH INC (KRYS) | Financial health 97th (free cash flow margin 58.5%, debt to equity 0).Financial health 97th (free cash flow margin 58.5%, debt to equity 0) and trend 85th (over the past 12 months this stock beat the market by 128.2 percentage points); weakest is valuation (24th, price to book 7.9, price to earnings 45.6). |
Health Care | 70.4 |
| 6 | Exelixis (EXEL) | Financial health 96th (free cash flow margin 48.1%, debt to equity 0).Financial health 96th (free cash flow margin 48.1%, debt to equity 0) and profitability 90th (operating margin 39.9%, return on equity 42.5%); weakest is capital return (18th, consecutive years of dividend increases 0 years). |
Health Care | 69.4 |
| 7 | Lilly (Eli) (LLY) | Profitability 95th (return on equity 92.6%, operating margin 42.2%).Profitability 95th (return on equity 92.6%, operating margin 42.2%) and growth 93rd (revenue growth year over year 49.6%, 3-year revenue CAGR 31.7%); weakest is valuation (17th, price to book 32.2, price to earnings 38.9). |
Health Care | 69.1 |
| 8 | Medpace (MEDP) | Financial health 88th (debt to equity 0, free cash flow margin 25.4%).Financial health 88th (debt to equity 0, free cash flow margin 25.4%) and profitability 84th (return on equity 110.2%, operating margin 21%); weakest is valuation (23rd, price to book 37.5, price to earnings 34.2). |
Health Care | 68.2 |
| 9 | PROTAGONIST THERAPEUTICS INC (PTGX) | Financial health 96th (free cash flow margin 46.3%, debt to equity 0).Financial health 96th (free cash flow margin 46.3%, debt to equity 0) and growth 90th (revenue growth year over year 34.8%); weakest is valuation (9th, price to earnings 141.2, price to book 11.3). |
Health Care | 68.1 |
| 13 | Amgen (AMGN) | Profitability 89th (return on equity 89.3%, operating margin 30.3%).Profitability 89th (return on equity 89.3%, operating margin 30.3%) and trend 87th (a strong uptrend, with buyers in control); weakest is valuation (32nd, price to book 20.3, price to earnings 27.2). |
Health Care | 66.8 |
Entered on 1 Sep 2026
AURINIA PHARMACEUTICALS INC (AUPH) — Entered 1 Sep 2026: score 79.4, rank 1 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Incyte (INCY) — Entered 1 Sep 2026: score 73.6, rank 2 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
HARMONY BIOSCIENCES HLDG INC (HRMY) — Entered 1 Sep 2026: score 72.4, rank 3 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
CAREDX INC (CDNA) — Entered 1 Sep 2026: score 72.3, rank 4 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
KRYSTAL BIOTECH INC (KRYS) — Entered 1 Sep 2026: score 70.4, rank 5 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Exelixis (EXEL) — Entered 1 Sep 2026: score 69.4, rank 6 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Medpace (MEDP) — Entered 1 Sep 2026: score 68.2, rank 8 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
PROTAGONIST THERAPEUTICS INC (PTGX) — Entered 1 Sep 2026: score 68.1, rank 9 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Left on 1 Sep 2026
Bristol Myers Squibb (BMY) — Left 1 Sep 2026: score 63.5, rank 24 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
Quest Diagnostics (DGX) — Left 1 Sep 2026: score 60.1, rank 32 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
Johnson & Johnson (JNJ) — Left 1 Sep 2026: score 64.8, rank 18 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
LIGAND PHARMACEUTICALS INC (LGND) — Left 1 Sep 2026: score 62.0, rank 29 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
NATIONAL HEALTHCARE CORP (NHC) — Left 1 Sep 2026: score 61.0, rank 30 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
ResMed | (RMD) — Left 1 Sep 2026: score 64.8, rank 19 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
Royalty Pharma (RPRX) — Left 1 Sep 2026: score 63.6, rank 23 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
West Pharmaceutical Services (WST) — Left 1 Sep 2026: score 57.2, rank 46 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
See every rebalance of this list →
Informational only — NOT financial advice.